Non-Small Cell Lung Cancer
Evidence-based overview of itraconazole in NSCLC, including pemetrexed combination data and angiogenesis relevance
Itraconazole has important early clinical relevance in non-small cell lung cancer, especially as an adjunct to pemetrexed.
Overview
The main NSCLC signal is from phase II combination data, which supports the anti-angiogenic and adjunctive-treatment logic of the drug.
Key human data
A phase II trial used itraconazole 200 mg daily with pemetrexed in advanced NSCLC
Progression-free survival was 5.5 months compared with 2.8 months in the pemetrexed-only group
Practical interpretation
This is one of the clearer examples of itraconazole being studied as a genuine adjunct rather than just a mechanistic curiosity.
References
Repurposing itraconazole for the treatment of cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.